BAX and malignant colon neoplasm: In fact, the isogenic DLD-1 Bax-Bak DKO colon cancer cells demonstrated significant increase in drug-resistance, as indicated by the resistant factor, towards the chemotherapeutic agents, including taxol, etoposide, cisplatin, doxorubicin and staurosporine, from 1.84 to 64.2 fold, when compared to the isogenic wild-type cancer cells, whereas neferine indicated similar IC50 values in both Bax-Bak wild-type and DKO cancer cells (Fig. 7D).